Merrimack Pharmaceuticals is 12.50 percent up even though modest market plunge

In this article I will examine Merrimack Pharmaceuticals. I will concentrate on why it could be a much better year for Merrimack Pharmaceuticals traders. Here I will also expose some important fundamental factors effecting the firm products and services and how it will impact Merrimack Pharmaceuticals outlook for investors this year. Macroaxis considers Merrimack Pharmaceuticals to be extremely dangerous. Merrimack Pharmaceuticals has Sharpe Ratio of -0.038, which conveys that the firm had -0.038% of return per unit of risk over the last 1 month. Macroaxis philosophy towards estimating risk of any stock is to look at both systematic and un-systematic factors of the business, including all available market data and technical indicators. Merrimack Pharmaceuticals exposes twenty-eight different technical indicators, which can help you to evaluate volatility that cannot be diversified away. Please be advised to verify Merrimack Pharmaceuticals Risk Adjusted Performance of (0.46) and Mean Deviation of 3.05 to check out the risk estimate we provide.
Published over a year ago
View all stories for Merrimack Pharmaceuticals | View All Stories
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.

Reviewed by Gabriel Shpitalnik

The company is under valued at 3.50 per share with modest projections ahead. The company secures a Beta (Market Risk) of 0.3202, which conveys that as returns on market increase, Merrimack Pharmaceuticals returns are expected to increase less than the market. However, during bear market, the loss on holding Merrimack Pharmaceuticals will be expected to be smaller as well. Even though it is essential to pay attention to Merrimack Pharmaceuticals price patterns, it is always good to be careful when utilizing equity historical price patterns. Macroaxis philosophy towards estimating future performance of any stock is to check both, its past performance charts as well as the business as a whole, including all available technical indicators. Merrimack Pharmaceuticals exposes twenty-eight different technical indicators, which can help you to evaluate its performance. Merrimack Pharmaceuticals has an expected return of -0.1808%. Please be advised to verify Merrimack Pharmaceuticals Semi Variance, and the relationship between Maximum Drawdown and Accumulation Distribution to decide if Merrimack Pharmaceuticals stock performance from the past will be repeated at some point in the near future.
The performance of Merrimack Pharmaceuticals in the marketplace will significantly impact your decision to invest in its stock. Revenue growth, profitability, competitive positioning, management quality, and industry trends can influence Merrimack Pharmaceuticals' stock prices. When investing in Merrimack Pharmaceuticals, there are several factors to consider and potential outcomes to expect. As a company performs well, its stock price may increase, allowing investors to benefit from price appreciation. However, Merrimack Stock can experience significant price fluctuations due to market conditions, economic factors, industry trends, or company-specific news. This is why investing in stocks such as Merrimack Pharmaceuticals carries risks, including the potential for capital loss. Stock prices can decline, and investors may incur losses if they sell shares at a lower price than their initial investment.

And What about dividends?

A dividend is the distribution of a portion of Merrimack Pharmaceuticals earnings, decided and managed by the company's board of directors and paid to a class of its shareholders. Note, announcements of dividend payouts are generally accompanied by a proportional increase or decrease in a company's stock price. Merrimack Pharmaceuticals dividend payments follow a chronological order of events, and the associated dates are important to determine the shareholders who qualify for receiving the dividend payment. Merrimack one year expected dividend income is about USD0.17 per share.
The value of Dividends Paid is estimated to slide to about 7.3 M. The value of Dividend Yield is estimated to slide to 0.31.
Last ReportedProjected for 2024
Dividends Paid7.7 M7.3 M
Dividend Yield 0.57  0.31 
Dividend Payout Ratio(1.44)(1.37)
Dividend Paid And Capex Coverage Ratio(1.06)(1.00)
Investing in stocks that pay dividends, such as stock of Merrimack Pharmaceuticals, is one of many strategies that are good for long-term investments. Ex-dividend dates are significant because investors in Merrimack Pharmaceuticals must own a stock before its ex-dividend date to receive its next dividend.
This type of analysis is very useful when you want to generate a past dividend schedule and payout information for Merrimack Pharmaceuticals. Then that information in the form of graph and calendar can be used to fully explain how Du Pont dividends can provide a real clue to its valuation.

How important is Merrimack Pharmaceuticals's Liquidity

Merrimack Pharmaceuticals financial leverage refers to using borrowed capital as a funding source to finance Merrimack Pharmaceuticals ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Merrimack Pharmaceuticals financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Merrimack Pharmaceuticals' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Merrimack Pharmaceuticals' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between Merrimack Pharmaceuticals's total debt and its cash.

Is Merrimack Pharmaceuticals valued adequately by the market?

Merrimack Pharmaceuticals has return on total asset (ROA) of (0.46) % which means that it has lost $0.46 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (0.56) % meaning that it created substantial loss on money invested by shareholders. Merrimack Pharmaceuticals price decrease over the last few months may encourage investors to take a closer look at the firm as it closed today at a share price of 2.35 on 87,287 in trading volume. The company executives were not very successful in positioning the firm resources to exploit market volatility in March. However, diversifying your holdings with Merrimack Pharmaceuticals or similar stocks can still protect your portfolio during high-volatility market scenarios. The stock standard deviation of daily returns for 30 days (very short) investing horizon is currently 4.75. This high volatility is attributed to the latest market swings and not so good earning reports for some of the Merrimack Pharmaceuticals partners. Merrimack Pharmaceuticals makes 77.96 m market capitalization. Merrimack Pharmaceuticals is selling at 2.70. That is 12.50 percent up. Today highest was 2.72. Merrimack Pharmaceuticals Revenue Per Employee is increasing over the last 8 years. The prevailing value of Merrimack Pharmaceuticals Revenue Per Employee is 475,218.
Merrimack Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that targets biomarker-defined cancers. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is headquartered in Cambridge, Massachusetts. Merrimack Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 27 people.
The bottom line, we see that Merrimack Pharmaceuticals Slowly supersedes market. The organization is under valued with very high odds of financial distress within the next 24 months. Our concluding buy-sell advice on the organization is Sell.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Rifka Kats do not own shares of Merrimack Pharmaceuticals. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com